Date: October 16, 2026

Strategic Initiative Summary

AstraZeneca Pharma India Limited has inaugurated a new corporate office in Mumbai, marking a significant expansion of its presence in India. The office inauguration represents a strategic move to support the company's next phase of growth through innovation.

Facility Details

  • New corporate office spans 25,600 square feet in Mumbai
  • Inaugurated on October 16, 2026
  • Inauguration ceremony attended by Honorable Shri Devendra Fadnavis, Chief Minister of Maharashtra, alongside senior government officials, dignitaries from embassies, and AstraZeneca team members

Business Context and Recent Performance

  • Introduced more than 25 new medicines and indications in India over the past three years
  • Currently running approximately 80 global clinical trials in India
  • Workforce of nearly 5,000 employees across the country
  • Focus therapy areas: Oncology, Biopharmaceuticals, and Rare Disease

Strategic Objectives

  • Strengthen ability to work with partners across healthcare ecosystem
  • Advance solutions addressing patient needs in India
  • Support closer engagement with stakeholders
  • Continue development of local talent and capabilities
  • Create opportunities for skilled employment and professional development
  • Support closer and more effective partnership with fast-evolving healthcare ecosystem

Leadership Commentary

Shri Devendra Fadnavis, Hon'ble Chief Minister of Maharashtra: Emphasized Maharashtra's strong pharmaceutical and life sciences ecosystem supported by skilled talent, leading institutions, and robust healthcare infrastructure. Noted that AstraZeneca's decision reflects confidence in the state's capabilities and potential as an innovation hub.

Praveen Rao Akkinepally, Country President and Managing Director: Stated that India is at an important inflection point in healthcare with growing need for earlier diagnosis, innovative treatments, and more equitable access. emphasized the company's focus on pioneering newer access pathways so life-saving therapies can reach every patient that needs them.

Arun Krishna, Non-Executive Director and Area Vice President, Asia: Highlighted India's importance as a contributor to AstraZeneca's growth across Asia. Noted the momentum of the business, evolution of the portfolio, and depth of talent in the country provides a strong foundation for future opportunities.

Operational Focus Areas

  • Leveraging AI and building solutions across the continuum of care – from prevention, awareness, to diagnosis and treatment
  • Working closely with governments and industry
  • Expanding access to innovation
  • Deepening partnerships
  • Addressing country's most pressing healthcare needs

Global Significance

  • India becomes one of the largest and most diverse footprints of the organization worldwide
  • Supports multiple functions including commercial operations, site management and monitoring, technology, research and development, and global business services

Company Background

AstraZeneca is a global science-led biopharmaceutical company focused on discovery, development, and commercialisation of prescription medicines across key therapy areas including Oncology, Biopharmaceuticals, and Rare Disease.